文献速递血液净化与透析

香港终末期肾病患者起始夜间家庭血透、医院血透与腹膜透析首两年直接与间接成本分析

Direct and indirect costs of end-stage renal disease patients in the first and second years after initiation of nocturnal home haemodialysis, hospital haemodialysis and peritoneal dialysis.
PubMed 文献 · Nephrol Dial Transplant · 2019-01-01

该成本分析基于402例维持性透析的终末期肾病患者,比较腹膜透析、医院血透和夜间家庭血透在起始第一年和第二年的直接与间接成本。从医疗提供者和社会视角,医院血透年成本最高;腹膜透析相对医院血透和夜间家庭血透更节省成本,但第二年的社会视角下夜间家庭血透成本最低。

要点

  • 医院血透在起始第一年和第二年的直接医疗成本及社会总成本均最高。
  • 从医疗提供者和社会视角,腹膜透析成本低于医院血透和夜间家庭血透。
  • 社会视角下第二年夜间家庭血透成本最低,低于腹膜透析和医院血透。

核心结论

  • 从医疗提供者和社会视角,腹膜透析相对医院血透和夜间家庭血透更节省成本,但第二年社会视角下夜间家庭血透成本最低。

研究设计与样本

  • 成本分析,纳入402例维持性透析的终末期肾病患者(腹膜透析189例、医院血透170例、夜间家庭血透43例),从医疗提供者和社会视角估算起始第一年和第二年的年成本,以2017年港元表示。

主要发现

  • 医疗提供者视角,医院血透起始第一年总年直接医疗成本均值±标准差为$400 057±62 822,腹膜透析为$118 467±15 559,夜间家庭血透为$223 358±18 055,P<0.001。
  • 医疗提供者视角,医院血透第二年总年直接医疗成本为$360 924±63 014,腹膜透析为$80 796±15 820,夜间家庭血透为$87 028±9059,P<0.001。
  • 社会视角,医院血透起始第一年总年成本为$452 151±73 327,腹膜透析为$189 191±61 735,夜间家庭血透为$242 038±28 281,P<0.001。
  • 社会视角,医院血透第二年总年成本为$413 017±73 501,腹膜透析为$151 520±60 353,夜间家庭血透为$105 708±23 853,P<0.001。

临床怎么用

  • 在规划终末期肾病透析方式时,可参考本成本数据评估腹膜透析、医院血透和夜间家庭血透的经济负担。
  • 医疗提供者和社会视角下,腹膜透析在起始两年内相对医院血透和夜间家庭血透更节省成本,但第二年社会视角下夜间家庭血透成本最低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To estimate the direct and indirect costs of end-stage renal disease (ESRD) patients in the first and second years of initiating peritoneal dialysis (PD), hospital-based haemodialysis (HD) and nocturnal home HD. METHODS: A cost analysis was performed to estimate the annual costs of PD, hospital-based HD and nocturnal home HD for ESRD patients from both the health service provider's and societal perspectives. Empirical data on healthcare resource use, patients' out-of-pocket costs, time spent on transportation and dialysis by ESRD patients and time spent by caregivers were analysed. All costs were expressed in Hong Kong year 2017 dollars. RESULTS: Analysis was based on 402 ESRD patients on maintenance dialysis (PD: 189; hospital-based HD: 170; and nocturnal home HD: 43). From the perspective of the healthcare provider, hospital-based HD had the highest total annual direct medical costs in the initial year (mean ± SD) (hospital-based HD = $400 057 ± 62 822; PD = $118 467 ± 15 559; nocturnal home HD = $223 358 ± 18 055; P < 0.001) and second year (hospital-based HD = $360 924 ± 63 014; PD = $80 796 ± 15 820; nocturnal home HD = $87 028 ± 9059; P < 0.001). From the societal perspective, hospital-based HD had the highest total annual costs in the initial year (hospital-based HD = $452 151 ± 73 327; PD = $189 191 ± 61 735; nocturnal home HD = $242 038 ± 28 281; P < 0.001) and second year (hospital-based HD = $413 017 ± 73 501; PD = $151 520 ± 60 353; nocturnal home HD = $105 708 ± 23 853; P < 0.001). CONCLUSIONS: This study quantified the economic burden of ESRD patients, and assessed the annual healthcare and societal costs in the initial and second years of PD, hospital-based HD and nocturnal home HD in Hong Kong. From both perspectives, PD is cost-saving relative to hospital-based HD and nocturnal home HD, except that nocturnal home HD has the lowest cost in the second year of treatment from the societal perspective. Results from this cost analysis facilitate economic evaluation in Hong Kong for health services and management targeted at ESRD patients.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Wong CKH, Chen J, Fung SKS, et al. Direct and indirect costs of end-stage renal disease patients in the first and second years after initiation of nocturnal home haemodialysis, hospital haemodialysis and peritoneal dialysis. Nephrol Dial Transplant. 2019. PMID: 30668781. doi:10.1093/ndt/gfy395

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。